ReviewCancer2025

Measurable residual disease (MRD) as a surrogate end point for clinical drug approval in acute myeloid leukemia (AML): Perspectives from the MRD Partnership and Alliance in AML Clinical Treatment Consortium.

Michael Boyiadzis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.